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Abstract
Tylophorine analogs exhibit a broad range of pharmacological activities, including anti-cancer, anti-inflammatory, anti-
autoimmune, and anti-virus effects. Structure-activity relationship study of different structure tylophorine analogs can
provide further understanding of their biological activity. Modifications on the E ring of the quinolizidine moiety of
cryptopleurine analogs changed the potency and the selective inhibitory effect on NF-kB, AP-1, and CRE signaling
pathways. Functional cryptopleurine analogs showed potent inhibition of NF-kB signaling pathway in both HepG2 and HEK-
293 cell lines. The E ring structure analogs also differed in suppression of protein translation, and expression of cyclin D1.
Our results showed that DCB-3503 or Rac-cryptopleurine could be a scaffold for modification to yield compounds with
different mechanisms of action.
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Introduction
Tylophorine alkaloids are natural products originally identified
in the Asclepiadaceae and Moracea family. Their claimed medical uses
include the treatment of cancer, lupus, and inflammation
[1,2,3,4,5,6]. NCI’s COMPARE program indicated that their
activity was distinct from other known anticancer compounds,
suggesting that this group of analogs have a novel mode of action
that is different from current chemotherapeutic compounds [1].
Tylophorine alkaloids, such as DCB-3500, DCB-3503, or Rac-
cryptopleurine (chemical structures shown in Fig. 1), inhibit
synthesis of protein, DNA, and RNA. DCB-3503 preferentially
downregulated express of proteins with short a half-life, e.g. cyclin
D1 [7,8]. They exhibit inhibitory effect on NF-kB signaling
pathway, but are less potent against activator protein-1 (AP-1), and
cyclic AMP response elements (CREs) signaling pathways [1,7,9].
Tylophorine analog DCB-3503 but not DCB-3500 is active
against HepG2 and PANC-1 xenografts in nude mice [1,2],
suggesting that the R14 hydroxyl group is important for in vivo
activity.
Due to the diverse and potent pharmacological activities of
tylophorine analogs, many groups including ours synthesize and
modify different tylophorine alkaloids analogs and study their
structure-activity relationship (SAR). This group of compounds
shares a common pentacyclic structure with the phenanthrene ring
conjugated with the indolizidine (five-member E ring) or
quinolizidine (six-member E ring) moiety. Previous SAR study
has found that cryptopleurine analogs with quinolizidine moiety
(Fig. 1) were more active than analogs with indolizidine moiety
against several cancer cell lines and NF-kB signaling pathway
in vitro [9]. In the present study, we further evaluated SAR of a
series of newly synthesized cryptopleurine analogs with modifica-
tions especially on the quinolizidine moiety.
Results and Discussion
Our previous work demonstrated that Rac-cryptopleurine with
the quinolizidine moiety (six-member E ring) is about 5 to 10
fold more potent than analogs with the indolizidine moiety (five-
member E ring) (DCB-3500 and DCB-3503) [9]. In the current
study, we analyzed the SAR of eleven cryptopleurine analogs
with modifications especially on the quinolizidine moiety. These
cryptopleurine analogs were previously reported by Dr. KH
Lee’s laboratory [10,11]. The hydroxylated analogs (YXM-109, -
110, -139, and -140) are recently synthesized [12].
The cytotoxicity of these compounds against human hepatoma
cell lines (HepG2 and Huh-7) is shown in Table 1 (The dose-cell
viability curves used to obtain the IC50 value is shown in Figure
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S1a and S1b). These compounds showed different selectivity
against HepG2 and Huh-7 cell lines, suggesting that the
mechanisms of action of different analogs could be cell-type
specific. Structurally, YXM-109, 110, 139, and 140 differ only in
the chirality and position of hydroxyl (-OH) group. The addition
of a (R)-hydroxyl group on the R13 position (YXM-110) decreased
the cytotoxicity to about seven fold in HepG2 cells and three fold
in Huh-7 cells compared to Rac-cryptopleurine. The addition of
an (S)-hydroxyl group on the R13 position (YXM-109) further
decreased the cytotoxicity in both cells lines. YXM-140 with an
(R)-hydroxyl group on the R12 position showed similar cytotoxic
potencies compared to YXM-109. However, the addition of an
(S)-hydroxyl group on the R12 position (YXM-139) resulted in loss
of potency against the tested cancer cell lines. Modifications on the
E-ring quinolizidine moiety, including substitution of carbon by
nitrogen or oxygen (YXM-66, 82, 93, and 101), replacing the six-
membered E-ring with a seven-membered E-ring (YXM-83) or
with a five-membered N-cyclopropylpyrrolidinyl E-ring (YXM-
93), caused the loss of cytotoxicity towards HepG2 and Huh-7 cell
lines. Together with our previous report, these newly synthesized
compounds showed similar spectrum of potency against A549,
DU145, KB, KBvin, SKBR3 cell lines to HepG2 and Huh 7 cell
lines as we reported in the present study [12]. The more potent
cryptopleurine analogs (Rac-cryptopleurine, YXM-109, YXM-
110, and YXM-140) exhibited moderate selectivity (nM IC50)
against KB, KBvin, and Huh 7 cell line. These results provided
important information that the structure requirements for the most
potent cytotoxic analogs for different cell lines appear to be the
same.
NF-kB plays important role in controlling inflammation, cancer
cell survival and death, and formation of chemoresistance [10,11].
Regulation of transcription factors including AP-1 and CRE
governs key steps in controlling cell proliferation, inflammation,
and apoptosis [13,14]. Those three signal transduction pathways
also interplayed among themselves. Inhibition of NF-kB signaling
pathway is involved in the inhibition of cancer cell growth and
suppression of inflammatory diseases in DCB-3503-treated mice
model [2,5,13,15]. DCB-3503, Rac-cryptopleurine, and their
functional analogs preferentially inhibited NF-kB to AP-1, and
CRE signaling pathways in HepG2 cell line [1,7,9]; therefore, we
determined the activities of these eleven new cryptopleurine
analogs to the above three signaling pathways in HepG2 and
HEK-293 cell lines (The dose-luciferase activity curves used to
obtain the IC50 value is shown in Figure S2a-S3c for HepG2 cells
and S3a-S3c for HEK-293 cells). Results in Table 2 obtained from
HepG2 cells showed that DCB-3503 and Rac-cryptopleurine
preferentially inhibited NF-kB signaling pathway. YXM-140 had
similar pattern of selectivity. YXM-109 and 110 had almost equal
potency against NF-kB and AP-1 signaling pathways. YXM-139
with a R12-(S)-OH substitution showed at least 1000-fold less
potent than its R13 -OH isomers (YXM-109, -110) and R12
enantioisomer (YXM-140). YXM-142 exhibited about 3-fold more
potent against AP-1 than against NF-kB signaling pathway. YXM-
93 and -139 inhibited CRE pathway preferentially in HepG2 cells.
While YXM-66, 82, 83, and 101 exhibited almost equal activities
Figure 1. The chemical structures of DCB-3503 and Rac-cryptopleurine.
doi:10.1371/journal.pone.0051138.g001
Table 1. The IC50 of tylophora alkaloids analogs on the
growth inhibition of HepG2 and Huh 7 cells.
HepG2 IC50
a (nM) Huh-7 IC50
a (nM)
DCB-3503 91.0611.2 b 91.7628.9














The IC50 of these compounds are significantly different (p,0.05) from each
other in different magnitude (nM vs mM); while compounds with the same
magnitude (nM vs nM and mM vs mM) are not significantly different from each
other (ANOVA analysis). a Values are means 6 SD of at least three experiments,
with each data point done in triplicate. b published.
doi:10.1371/journal.pone.0051138.t001
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to the three tested signaling pathways in HepG2 cells. Compar-
atively in HEK-293 cell lines (Table 2), Rac-cryptopleurine,
YXM-109, 110, 140, and 82 showed potent inhibition on both
NF-kB and AP-1 signaling pathways. The selectivity of YXM-93
and YXM-66 changed to AP-1 pathway. YXM-139 was active
against both AP-1 and CRE signaling pathway. Despite the
switches of selectivity against different signaling pathways of those
less potent cryptopleurine analogs (YXM-66, 82, 93, 101, 139,
142), the sensitivity of more potent analogs (DCB-3503, Rac-
cryptopleruine, YXM-83, 142, and 101) against NF-kB signaling
pathway did not change in both HepG2 and HEK-293 cell lines.
This result suggests that inhibition of NF-kB rather than AP-1 and
CRE signaling pathway could be one of the key factors related to
the potency of cryptopleurine analogs.
Activation of NF-kB will induce the expression of Cox 2 [16]
and iNOS [17], we then analyzed the effect of the treatment of
cryptopleurine analogs on these two NF-kB pathway downstream
targets by Western blot. Cryptopleurine analogs down-regulated
the expression of both Cox 2 and iNOS in HepG2 cells at their
IC50 concentration against NF-kB pathway (Fig. 2). This
confirmed the inhibition of NF-kB pathway by cryptopleurine
analogs. These results showed that modifications on the E-ring of
cryptopleurine analogs are directly related to their selectivity
against NF-kB, AP-1, and CRE signaling pathways in HepG2 cell
line. Structural analogs can not only lead to altered potency [9],
but also change mechanisms of action.
DCB-3503 suppressed the expression of cellular proteins with a
short half-life, for instance cyclin D1 and p53 [8]. Therefore, we
examined the effect of the treatment of functional crytopleurine
analogs on the expression of cyclin D1. Figure 3 showed that the
treatment of Rac-cryptopleurine, and DCB-3503 with about three
times IC50 concentration decreased more than 70% of cyclin D1
expression. The treatment of YXM-109, -110, and -140 also
showed more than 50% inhibitory effect on cyclin D1 expression
at their IC50 concentration in HepG2 cells (Fig. 3). However, the
treatment of YXM-139 did not change cyclin D1 expression level
at its IC50 concentration (Fig. 3).
We previously demonstrated that DCB-3503 inhibited protein
synthesis at the elongation step of translation, which could be the
basis of inhibiting cell growth and TNF/NF-kB pathway [8]. The
effect of some cryptopleurine analogs on synthesis of cellular
proteins was examined. Figure 4 showed that DCB-3503, Rac-
cryptopleurine, YXM-109, 110, and 140 inhibited incorporation
of [35S]-methionine/cysteine into newly synthesized proteins after
treatment for 4 hours at their IC50 concentration. However, the
Table 2. The IC50 of the inhibitory effect of tylophora alkaloids on NF-kB, AP-1, and CRE signalging pathways in HepG2 and HEK-
293 cells.
NF-kB IC50 (nM) AP-1 IC50 (nM) CRE IC50 (nM)
HepG2 HEK-293 HepG2 HEK-293 HepG2 HEK-293
DCB-3503 85.067.1 a 37.6619.7 15006330 a 12562.5 10676231 a 18156970
Rac-cryptopleurine 1.560.28 a 7.161.3 15.060.14 a 8.863.0 30.060.58 a 24.2610.6
YXM-109 10.060.11 22.269.6 20.060.17 18.661.1 30006503 845062190
YXM-110 10.060.12 20.261.5 15.060.14 5.662.0 500670 4606230
YXM-140 15.060.14 22.467.9 41.2618.0 16.762.6 15006120 22006280
YXM-142 153.564.9 425677 50.060.2 60.161.5 30.060.17mM 3.961.4 mM
NF-kB IC50 (mM) AP-1 IC50 (mM) CRE IC50 (mM)
HepG2 HEK-293 HepG2 HEK-293 HepG2 HEK-293
YXM-66 .30.0 33.5613.4 .30.0 5.461.2 .30.0 .30.0
YXM-82 15.060.32 1.160.6 5.060.85 0.6260.03 .30.0 .30.0
YXM-83 3.060.1 5.060.4 1.560.85 5.860.7 1.560.14 3.160.8
YXM-93 15.060.71 26.368.2 15.060.67 1.9560.7 1.060.13 .30.0
YXM-101 .30.0 120.0614.1 .30.0 30.060.1 .30.0 .30.0
YXM-139 .30.0 79.4615.2 .30.0 12.063.9 3.060.64 7.362.4
Values are means 6 SD of at least three experiments, with each data point done in triplicate. The IC50 concentrations of these compounds are significantly different
(p,0.05) from each other in between nM and mM concentrations; while compounds with the same concentration level (nM vs nM and mM vs mM) are not significantly
different (ANOVA analysis). a published.
doi:10.1371/journal.pone.0051138.t002
Figure 2. Crytopleurine analogs inhibited Cox 2 and iNOS
expression. HepG2 cells were treated with crytopleurine analogs and
DCB-3503 with the dosage as indicated in the figure for 4 hours. Protein
level of Cox 2 and iNOS was analyzed by Western blot. Results were
representative of three independent experiments.
doi:10.1371/journal.pone.0051138.g002
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treatment of YXM-139 did not show similar inhibition effect on
protein synthesis under the same conditions.
The effect of cryptopleurine analogs on protein translation was
examined by capped luciferase mRNA with T3 promoter and poly
(A) tail in Retic lysate in vitro translation system. DCB-3503 and
Rac-cryptopleurine inhibited about 50% of translation of lucifer-
ase mRNA at 250 nM and 500 nM, respectively (Fig. 5). YXM-
109 and 110 has significantly inhibitory effect on luciferase mRNA
translation at 250 nM (p,0.05); however, YXM-139 and 140 did
not inhibit translation under the same condition at 500 nM and
250 nM, respectively (Fig. 5). This suggested that modifications of
the E ring not only altered cytotoxicity, but also changed their
activity against protein translation.
Conclusion
Tylophorine analogs with introduction of different moieties (e.g.
N or O) in the E-ring have less potency against the growth of
HepG2 and Huh-7 cell lines, and some of those are no longer
functional analogs. Introduction of the hydroxyl group into the E-
ring altered the cytotoxicity of cryptopleurine ananlogs, and the
chirality of the hydroxyl group is critical determination factor in
the cytotoxicity. Cryptopleurine analogs with 6-member E-ring
are more potent than 7-member E-ring analogs (Fig. 6 for results
of HepG2 cells and Fig. S4 for results of HEK-293 cells). Together
with results from our previous SAR studies [9], we propose the
following order of potency in terms of NF-kB inhibition and
cytotoxicity: six member E-ring with R14a-(R)-hydrogen.five
member E-ring with R13a-(R)-hydrogen.five member E-ring
with R13a-(S)-hydrogen..six member E-ring with R14a-(R)-
hydrogen. The results we obtained suggest that the E ring size may
be a critical determination factor for the interaction of crypto-
pleurine analogs to their molecular targets, and molecular target of
cryptopleurine analogs may not be identical. Changing structure
of compound may not only be reflected in potency, but also
determined the mode of action. Since the biochemical determi-
nants of the primary target(s) of these compounds may vary, the
selectivity against different signaling pathways could be cell type
specific. This was demonstrated by the comparative study of
HepG2 and HEK-293 cell lines. Their potency against HepG2
cell growth correlates well with the inhibitory activity against
Figure 3. Functional crytopleurine analogs inhibited cyclin D1 expression. HepG2 cells were treated with crytopleurine analogs and DCB-
3503 with the dosage as indicated in the figure for 2 and 4 hours. Cyclin D1 protein level was analyzed by Western blot. The band intensity of Cyclin
D1 on Western blot was normalized with that of b-actin by densitometer scanning, and presented as a chart below. Results were mean 6 SD from
three independent experiments.
doi:10.1371/journal.pone.0051138.g003
Figure 4. Effect of cryptopleurine analogs treatment for 4 hours on protein synthesis profile assessed by [35S]-methionine/cysteine
incorporation in HepG2 cells. The incorporation of [35S]-methionine/cysteine was measure by scintillation counter, and presented as percentage
to untreated control cells. (**, p,0.01; *, p,0.05).
doi:10.1371/journal.pone.0051138.g004
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protein synthesis and TNF/NF-kB pathway. Tylophorine or Rac-
cryptopleurine could be a good scaffold for synthesis of biological
active compound with diverse action. We are in the process of
evaluating the in vivo antitumor activity of selected cryptopleurine
analogs with R15 hydroxyl group.
Figure 5. Cryptopleurine analogs inhibited luciferase translation in Retic lysate IVT system. Results were mean 6 SD from three
independent experiments. (**, p,0.01; *, p,0.05).
doi:10.1371/journal.pone.0051138.g005
Figure 6. Schematic description of the SAR of cryptopleurine analogs with modification on the E-ring in HepG2 cell line.
doi:10.1371/journal.pone.0051138.g006
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Materials and Methods
Materials
DCB-3503 (NSC-716802) was synthesized in Dr. D. C. Baker’s
laboratory (The University of Tennessee, TN). Crytopleurine
analogs were synthesized in Dr. K. H. Lee’s laboratory (University
of North Carolina, NC). Cell culture media, fetal bovine serum
(FBS) were purchased from Invitrogen (Carlsbad, CA). All
chemicals except otherwise noted were purchased from Sigma-
Aldrich (St. Louis, MO).
Cell Lines and Growth Conditions
Cell lines were obtained from the American Type Culture
Collection (ATCC). HepG2 cells were maintained in RPMI 1640
medium supplemented with 10% FBS. HepG2 stable cell lines
harboring NF-kB, AP-1, CRE response elements in pGL4 vector
(Promega) were maintained in the presence of 0.8 mg/ml G418.
Huh-7 and HEK-293 cells were maintained in DMEM containing
4.5 g/l glucose supplemented with 10% FBS. All cell lines were
maintained in a humidified incubator with an atmosphere of 95%
air and 5% CO2 at 37uC.
Cytotoxicity Assay
Ten thousands cells/well were plated in 24-well plates. After
overnight incubation, cells were treated with drugs for 72 hours.
Cells were fixed and stained with 0.5% methylene blue in 50%
ethanol for 2 hours at room temperature, followed by washing
with tap water to remove excess color. Plates were dried and then
resuspended in 1% sarkosyl and incubate for 3 hours at room
temperature. Cell growth was quantitated based on the amount of
methylene blue adsorbed into cellular proteins measured by
spectrophotometer (Molecular Devices) at 595 nm. IC50 was
defined as the concentration of drug that inhibited cell growth by
50% after continuous drug exposure for 72 hours [1].
Signaling Pathway Reporter Assay
HepG2 and HEK-293 cell lines stably harboring NF-kB, AP-1,
and CRE response elements in pGL4.0 luciferase vector (Promega)
were used for the signaling pathway reporter assay [1]. Cells were
treated with 50 ng/ml TNF-a to stimulate NF-kB signaling
pathway, 10 ng/ml TPA to stimulate AP-1, and 1 mM forskolin to
stimulate CRE signaling pathway for 1 hour priory to addition of
compounds for another 4 hours. Medium was removed at the end
of the treatment, and cell extracts were prepared and luciferase
activity was measured by Luciferase assay kit (Promega) according
to the manufacturer’s instructions. IC50 was defined as the
concentration of drug that inhibited stimulator-triggered luciferase
reporter activation by 50% after continuous drug exposure for 4
hours.
Western Blot Analysis
Western blot analysis was done using primary antibodies against
Cox 2 (Cell Signaling Technology), iNOS (Abcam), cyclin D1
(Santa Cruz Biotechnology), and b-actin (Sigma-Aldrich) at
optimal dilution [8].
[35S]-amino Acid Mixture Incorporation Assay
The incorporation assay was done followed by the protocol
described previously [8]. In brief, HepG2 cells treated with drugs
were labeled with 50 mCi/ml [35S]-methionine/cysteine (Perki-
nElmer) for 30 minutes before harvest. Incorporation of [35S]-
methionine/cysteine was determined by scintillation counter.
In vitro Transcription
The detailed protocol for in vitro transcription was reported
previously [8]. Luciferase encoding plasmid T3 luciferase was
linearized by BamHI, and was used as the template for in vitro
transcription. Capped luciferase mRNA was generated by
mMESSAGE mMACHINE high yield capped RNA transcription
kit containing T3 RNA polymerase (Ambion). The in vitro
transcribed mRNAs were purified by MEGAclear kit (Ambion);
and the integrity of mRNA was examined by Bioanalyzer (Agilent
Technologies, Santa Clara, CA). The purified mRNAs were used
for in vitro translation experiments.
In vitro Translation
In vitro translation was performed by Retic Lysate IVTTM
(Ambion) as described previously [8]. The in vitro translation
mixtures containing 50 ng/ml T3 luciferase mRNA was incubated
for 90 minutes at 30uC. Translation products of T3 luciferase were
measured by luciferase assay.
Statistical Analysis
Data were analyzed by ANOVA and the Bonferroni multiple
comparision test by GraphPad Prism 5 software. The difference
was considered to be statistically significant when p,0.05.
Supporting Information
Figure S1 Dose-cell viability curves for DCB-3503 and
cryptopleurine analogs in HepG2 (a) and Huh-7 (b) cell lines.
Graphs were simplified by showing the mean value from three
independent experiments.
(TIF)
Figure S2 Dose-luciferase activity curves for DCB-3503 and
cryptopleurine analogs against NF-kB (a), AP-1 (b), and CRE (c)
signaling pathways in HepG2 cell line. Graphs were simplified by
showing the mean value from three independent experiments.
(TIF)
Figure S3 Dose-luciferase activity curves for DCB-3503 and
cryptopleurine analogs against NF-kB (a), AP-1 (b), and CRE (c)
signaling pathways in HEK-293 cell line. Graphs were simplified
by showing the mean value from three independent experiments.
(TIF)
Figure S4 Schematic description of the SAR of crypto-
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